Film digitizer firm Howtek had a difficult 1997. While the company did show some improvement on the bottom line, Howtek's revenues declined 30% for the year.Revenues were $7.9 million, compared with the $11.3 million reported in the same period last
Film digitizer firm Howtek had a difficult 1997. While the company did show some improvement on the bottom line, Howtek's revenues declined 30% for the year.
Revenues were $7.9 million, compared with the $11.3 million reported in the same period last year. The Hudson, NH-based company had a net loss of $832,000, compared with a net loss of $6.1 million in 1996.
In the fourth quarter (end-December), revenues were $2.1 million, a 34% dip from the $3.1 million reported last year. Howtek had a net loss of $1.3 million, compared with a net loss of $746,000 in the same period in 1996.
To make up for declining sales volume, Howtek is developing a plan to broaden its product line by securing new scanners and related products from other manufacturers on an OEM basis. Howtek would then privately label the new products. Price reductions on certain products are planned, and the company is also evaluating additional complementary products and markets.
One key area of focus in the future will be its x-ray film digitizer offerings. Commercial production has begun on the firm's first compact, automated-feed x-ray film digitizer, and Howtek views the x-ray market as a substantial growth opportunity.
The company has also instituted some cost-containment measures. On Jan. 30, Howtek significantly reduced the number of employees, as well as certain operating expenses. Improved budgeting and cost controls were also implemented.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.